Go Deep
Immunovant, Inc.
Immunovant, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,038 | -10.2 | 8.06 | 0.00 | 2,734.16 |
| Oct 2026 | 19,241 | -9.9 | 7.84 | 0.00 | 2,649.04 |
| Oct 2026 | 19,339 | -10.0 | 7.73 | 0.00 | 2,612.38 |
| Oct 2026 | 19,535 | -9.5 | 7.51 | 0.00 | 2,531.73 |
| Oct 2026 | 19,311 | -9.8 | 7.76 | 0.00 | 2,618.83 |
| Oct 2026 | 19,068 | -10.1 | 8.03 | 0.00 | 2,710.80 |
| Oct 2026 | 19,121 | -10.1 | 7.97 | 0.00 | 2,684.24 |
| Oct 2026 | 18,940 | -10.3 | 8.17 | 0.00 | 2,746.77 |
| Oct 2026 | 19,113 | -10.1 | 7.98 | 0.00 | 2,692.76 |
Immunovant, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -153,224,000.0 | -147,856,000.0 | -110,635,000.0 | -126,502,000.0 |
| EPS | -0.8 | -0.7 | -0.6 | -0.7 |
Immunovant, Inc. Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -505,606,000.0 | -413,840,000.0 | -259,336,000.0 | -210,960,000.0 |
| EPS | -2.8 | -2.7 | -1.9 | -1.7 |
Immunovant, Inc. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 957,014,000.0 | 776,222,000.0 | 666,365,000.0 | 405,838,000.0 | — |
| Total Liabilities | 104,422,000.0 | 68,775,000.0 | 48,608,000.0 | 43,344,000.0 | — |
| Total Equity | 852,592,000.0 | 707,447,000.0 | 617,757,000.0 | 362,494,000.0 | — |
Owes vs Owns
Immunovant, Inc. owed $0.14 for every $1 it owned in Jun 2026, up from $0.11 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.14× | 0.11× | 0.09× | 0.07× | 0.11× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Immunovant, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Mar 2026
Cash & short-term investments 94.3%Other assets 5.3%
How it's funded — Mar 2026
Payables 0.8%Other liabilities 10.1%Shareholders' equity 89.1%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 902.1 | 714.0 | 635.4 | 376.5 |
| Receivables | 3.9 | 2.5 | 5.5 | 0.9 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.5 | 0.9 | 0.6 | 1.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 50.4 | 58.8 | 24.9 | 26.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.1 | 0.1 | 0.1 | 1.2 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 7.5 | 17.7 | 7.2 | 1.4 |
| Other liabilities | 96.8 | 51.0 | 41.3 | 40.8 |
| Shareholders' equity | 852.6 | 707.4 | 617.8 | 362.5 |
| Net tangible assets | 852.6 | 707.4 | 617.8 | 362.5 |
Immunovant, Inc. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -407,310,000.0 | -375,874,000.0 | -214,227,000.0 | -188,193,000.0 | — |
| Investing Activities | -8,000.0 | -759,000.0 | -360,000.0 | -197,000.0 | — |
| Financing Activities | 595,756,000.0 | 454,492,000.0 | 472,427,000.0 | 70,885,000.0 | — |